Orchid Chemicals & Pharmaceuticals has received the formal approval from USFDA for its abbreviated new drug application (ANDA) for Cefprozil oral suspension of 125 mg/5 ml and 250 mg/5 ml.According to a release issued by the company to the BSE today, the current US market size for Cefprozil oral suspension is $120 million. "The company is launching the product in the US through its marketing alliance partner Par Pharmaceuticals," the release added.Cefprozil is the generic version of Bristol-Myers Squibb's Cefzil, the release said.
